Despite delayed kinetics, people living with HIV achieve equivalent antibody function after SARS-CoV-2 infection or vaccination

The kinetics of Fc-mediated functions following SARS-CoV-2 infection or vaccination in people living with HIV (PLWH) are not known. We compared SARS-CoV-2 spike-specific Fc functions, binding, and neutralization in PLWH and people without HIV (PWOH) during acute infection (without prior vaccination) with either the D614G or Beta variants of SARS-CoV-2, or vaccination with ChAdOx1 nCoV-19. Antiretroviral treatment (ART)–naïve PLWH had significantly lower levels of IgG binding, neutralization, and antibody-dependent cellular phagocytosis (ADCP) compared with PLWH on ART. The magnitude of antibody-dependent cellular cytotoxicity (ADCC), complement deposition (ADCD), and cellular trogocytosis (ADCT) was differentially triggered by D614G and Beta. The kinetics of spike IgG-binding antibodies, ADCC, and ADCD were similar, irrespective of the infecting variant between PWOH and PLWH overall. However, compared with PWOH, PLWH infected with D614G had delayed neutralization and ADCP. Furthermore, Beta infection resulted in delayed ADCT, regardless of HIV status. Despite these delays, we observed improved coordination between binding and neutralizing responses and Fc functions in PLWH. In contrast to D614G infection, binding responses in PLWH following ChAdOx-1 nCoV-19 vaccination were delayed, while neutralization and ADCP had similar timing of onset, but lower magnitude, and ADCC was significantly higher than in PWOH. Overall, despite delayed and differential kinetics, PLWH on ART develop comparable responses to PWOH, supporting the prioritization of ART rollout and SARS-CoV-2 vaccination in PLWH.

[1]  D. Lauffenburger,et al.  Differences in HPV-specific antibody Fc-effector functions following Gardasil® and Cervarix® vaccination , 2023, npj Vaccines.

[2]  W. Bierman,et al.  Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV in the Netherlands: A nationwide prospective cohort study , 2022, PLoS medicine.

[3]  S. Madhi,et al.  Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b–2a trial , 2022, The Lancet Infectious Diseases.

[4]  O. Hyrien,et al.  Lower SARS-CoV-2–specific humoral immunity in people living with HIV-1 recovered from nonhospitalized COVID-19 , 2022, JCI insight.

[5]  A. Meyerhans,et al.  Anti-SARS-COV-2 specific immunity in HIV immunological non-responders after mRNA-based COVID-19 vaccination , 2022, Frontiers in Immunology.

[6]  C. Agrati,et al.  Immunogenicity to COVID-19 mRNA vaccine third dose in people living with HIV , 2022, Nature Communications.

[7]  T. Ndung’u,et al.  HIV viremia is associated with compromised SARS-CoV-2 Beta variant neutralization. , 2022, The Journal of infectious diseases.

[8]  T. de Oliveira,et al.  Persistent SARS-CoV-2 infection with accumulation of mutations in a patient with poorly controlled HIV infection , 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  D. Lauffenburger,et al.  The Kinetics of SARS-CoV-2 Antibody Development Is Associated with Clearance of RNAemia , 2022, mBio.

[10]  V. Calvez,et al.  High seroconversion rate and SARS-CoV-2 Delta neutralization in people with HIV vaccinated with BNT162b2 , 2022 .

[11]  D. Podzamczer,et al.  Long-lasting adaptive immune memory specific to SARS-CoV-2 in convalescent coronavirus disease 2019 stable people with HIV , 2022, AIDS.

[12]  J. Montaner,et al.  People with HIV receiving suppressive antiretroviral therapy show typical antibody durability after dual COVID-19 vaccination, and strong third dose responses , 2022, The Journal of infectious diseases.

[13]  C. Pade,et al.  Generation of Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants on the B.1.1.7 Lineage in 3 Patients With Advanced Human Immunodeficiency Virus (HIV)-1 Disease , 2022, Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America.

[14]  N. Ford,et al.  Clinical features of, and risk factors for, severe or fatal COVID-19 among people living with HIV admitted to hospital: analysis of data from the WHO Global Clinical Platform of COVID-19 , 2022, The Lancet HIV.

[15]  S. Madhi,et al.  Influenza Vaccination Results in Differential Hemagglutinin Stalk-Specific Fc-Mediated Functions in Individuals Living With or Without HIV , 2022, Frontiers in Immunology.

[16]  C. Agrati,et al.  Humoral and Cellular Immune Response Elicited by mRNA Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in People Living With Human Immunodeficiency Virus Receiving Antiretroviral Therapy Based on Current CD4 T-Lymphocyte Count , 2022, Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America.

[17]  J. Andriesen,et al.  High Asymptomatic Carriage With the Omicron Variant in South Africa , 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  D. Lauffenburger,et al.  mRNA-1273 and BNT162b2 COVID-19 vaccines elicit antibodies with differences in Fc-mediated effector functions , 2022, Science Translational Medicine.

[19]  M. Alcaide,et al.  A Longitudinal Analysis of SARS-CoV-2 Antibody Responses Among People With HIV , 2022, Frontiers in Medicine.

[20]  D. Hagin,et al.  SARS-CoV-2 Humoral and Cellular Immune Responses of Patients With HIV After Vaccination With BNT162b2 mRNA COVID-19 Vaccine in the Tel-Aviv Medical Center , 2022, Open forum infectious diseases.

[21]  N. Sullivan,et al.  SARS-CoV-2 Beta and Delta variants trigger Fc effector function with increased cross-reactivity , 2022, Cell Reports Medicine.

[22]  D. Vézina,et al.  A Fc-enhanced NTD-binding non-neutralizing antibody delays virus spread and synergizes with a nAb to protect mice from lethal SARS-CoV-2 infection , 2022, Cell Reports.

[23]  T. Ndung’u,et al.  SARS-CoV-2 prolonged infection during advanced HIV disease evolves extensive immune escape , 2022, Cell Host & Microbe.

[24]  T. Ndung’u,et al.  Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and Ad26.CoV2.S Vaccination in People Living With Human Immunodeficiency Virus (HIV) , 2021, Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America.

[25]  M. Peluso,et al.  Differences in Post-mRNA Vaccination SARS-CoV-2 IgG Concentrations and Surrogate Virus Neutralization Test Response by HIV Status and Type of Vaccine: a Matched Case-Control Observational Study. , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  M. Peluso,et al.  Differences in Post-mRNA Vaccination Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Immunoglobulin G (IgG) Concentrations and Surrogate Virus Neutralization Test Response by Human Immunodeficiency Virus (HIV) Status and Type of Vaccine: A Matched Case-Control Observational Study , 2021, Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America.

[27]  D. Consonni,et al.  Anti-spike antibodies and neutralising antibody activity in people living with HIV vaccinated with COVID-19 mRNA-1273 vaccine: a prospective single-centre cohort study , 2021, The Lancet Regional Health - Europe.

[28]  H. Bundgaard,et al.  Humoral response to two doses of BNT162b2 vaccination in people with HIV , 2021, Journal of internal medicine.

[29]  E. Wolf,et al.  Humoral response to SARS-CoV-2 vaccines in people living with HIV , 2021, Infection.

[30]  J. Montaner,et al.  Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapy , 2021, medRxiv : the preprint server for health sciences.

[31]  P. Klenerman,et al.  Durability of ChAdOx1 nCov-19 (AZD1222) vaccination in people living with HIV - responses to SARS-CoV-2, variants of concern and circulating coronaviruses , 2021 .

[32]  Kyle J. Hunter,et al.  SARS-CoV-2 incidence, testing rates, and severe COVID-19 outcomes among people with and without HIV , 2021, AIDS.

[33]  T. Ndung’u,et al.  Similar antibody responses against SARS-CoV-2 in HIV uninfected and infected individuals on antiretroviral therapy during the first South African infection wave. , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[34]  T. Ndung’u,et al.  Similar Antibody Responses Against Severe Acute Respiratory Syndrome Coronavirus 2 in Individuals Living Without and With Human Immunodeficiency Virus on Antiretroviral Therapy During the First South African Infection Wave , 2021, Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America.

[35]  S. Madhi,et al.  Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial , 2021, The Lancet HIV.

[36]  V. Martel-Laferrière,et al.  Covid-19 vaccine immunogenicity in people living with HIV-1 , 2021, bioRxiv.

[37]  D. Lauffenburger,et al.  Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination , 2021, Cell Reports Medicine.

[38]  R. Shafer,et al.  SARS-CoV-2 Neutralization Resistance Mutations in Patient with HIV/AIDS, California, USA , 2021, Emerging infectious diseases.

[39]  O. Laeyendecker,et al.  The BNT162b2 mRNA Vaccine Elicits Robust Humoral and Cellular Immune Responses in People Living With Human Immunodeficiency Virus (HIV) , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[40]  P. Klenerman,et al.  Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial , 2021, The Lancet HIV.

[41]  H. Schuitemaker,et al.  Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans , 2021, Nature.

[42]  M. Peluso,et al.  SARS-CoV-2 seroprevalence, and IgG concentration and pseudovirus neutralising antibody titres after infection, compared by HIV status: a matched case-control observational study , 2021, The Lancet HIV.

[43]  A. Casadevall,et al.  Markers of Polyfunctional SARS-CoV-2 Antibodies in Convalescent Plasma , 2021, mBio.

[44]  A. Huppert,et al.  Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1 , 2021, Clinical Microbiology and Infection.

[45]  L. Morris,et al.  Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351) , 2021, The New England journal of medicine.

[46]  F. Tanser,et al.  Beyond HIV prevalence: identifying people living with HIV within underserved areas in South Africa , 2021, BMJ Global Health.

[47]  L. Morris,et al.  SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma , 2021, Nature Medicine.

[48]  S. Rowland-Jones,et al.  Characterization of humoral and SARS-CoV-2 specific T cell responses in people living with HIV , 2021, Nature Communications.

[49]  David R. Holtgrave,et al.  COVID-19 Outcomes Among Persons Living With or Without Diagnosed HIV Infection in New York State , 2021, JAMA network open.

[50]  K. Liang,et al.  People Living with HIV Easily lose their Immune Response to SARS-CoV-2: Result From A Cohort of COVID-19 Cases in Wuhan, China , 2021, Research square.

[51]  James D. Allen,et al.  Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions and monocytes for optimal therapeutic protection , 2020, bioRxiv.

[52]  Nguyen H. Tran,et al.  Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses , 2020, Nature Medicine.

[53]  M. Davenport,et al.  Decay of Fc-dependent antibody functions after mild to moderate COVID-19 , 2020, Cell Reports Medicine.

[54]  K. Bhaskaran,et al.  HIV infection and COVID-19 death: a population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform , 2020, The Lancet HIV.

[55]  G. Koh Faculty Opinions recommendation of Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK , 2020, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[56]  Nguyen H. Tran,et al.  Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK , 2020, Lancet.

[57]  C. Sabin,et al.  Outcomes of Coronavirus Disease 2019 (COVID-19) Related Hospitalization Among People With Human Immunodeficiency Virus (HIV) in the ISARIC World Health Organization (WHO) Clinical Characterization Protocol (UK): A Prospective Observational Study , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[58]  C. Sabin,et al.  Outcomes of Coronavirus Disease 2019 (COVID-19) Related Hospitalization Among People With Human Immunodeficiency Virus (HIV) in the ISARIC World Health Organization (WHO) Clinical Characterization Protocol (UK): A Prospective Observational Study , 2020, Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America.

[59]  D. Lauffenburger,et al.  Compromised Humoral Functional Evolution Tracks with SARS-CoV-2 Mortality , 2020, Cell.

[60]  M. Nussenzweig,et al.  Antibody potency, effector function and combinations in protection from SARS-CoV-2 infection in vivo , 2020, bioRxiv.

[61]  L. Morris,et al.  Risk Factors for Coronavirus Disease 2019 (COVID-19) Death in a Population Cohort Study from the Western Cape Province, South Africa , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[62]  Kira L. Newman,et al.  Distinct Early Serological Signatures Track with SARS-CoV-2 Survival , 2020, Immunity.

[63]  D. Lauffenburger,et al.  Single-Shot Ad26 Vaccine Protects Against SARS-CoV-2 in Rhesus Macaques , 2020, Nature.

[64]  R. Baric,et al.  DNA vaccine protection against SARS-CoV-2 in rhesus macaques , 2020, Science.

[65]  K. Kim,et al.  What Is COVID-19? , 2020, Frontiers for Young Minds.

[66]  G. Canderan,et al.  Monocyte Dysfunction, Activation, and Inflammation After Long-Term Antiretroviral Therapy in an African Cohort , 2019, The Journal of infectious diseases.

[67]  G. Alter,et al.  A high-throughput, bead-based, antigen-specific assay to assess the ability of antibodies to induce complement activation , 2019, Journal of immunological methods.

[68]  Jeffrey W. Eaton,et al.  Mapping HIV prevalence in sub-Saharan Africa between 2000 and 2017 , 2019, Nature.

[69]  L. Morris,et al.  Measuring the ability of HIV-specific antibodies to mediate trogocytosis. , 2018, Journal of immunological methods.

[70]  D. Rodríguez-Sanz,et al.  Footwear used by older people and a history of hyperkeratotic lesions on the foot , 2017, Medicine.

[71]  Peter J. Hogarth,et al.  Dimeric FcγR Ectodomains as Probes of the Fc Receptor Function of Anti-Influenza Virus IgG , 2016, The Journal of Immunology.

[72]  J. Margolick,et al.  The effect of HAART-induced HIV suppression on circulating markers of inflammation and immune activation , 2015, AIDS.

[73]  Jerome H. Kim,et al.  Polyfunctional Fc-Effector Profiles Mediated by IgG Subclass Selection Distinguish RV144 and VAX003 Vaccines , 2014, Science Translational Medicine.

[74]  M. Proschan,et al.  B cells in early and chronic HIV infection: evidence for preservation of immune function associated with early initiation of antiretroviral therapy. , 2010, Blood.

[75]  D. Irvine,et al.  A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples. , 2010, Journal of immunological methods.

[76]  J. V. van Dissel,et al.  Restoration of the antibody response upon rabies vaccination in HIV-infected patients treated with HAART , 2009, AIDS.

[77]  L. McHugh World Health Organization: A Fact Sheet , 1996 .

[78]  OUP accepted manuscript , 2022, Clinical Infectious Diseases.

[79]  M. Plana,et al.  Effects of highly active antiretroviral therapy on vaccine-induced humoral immunity in HIV-infected adults. , 2010, HIV medicine.